Variant report
Variant | nsv516321 |
---|---|
Chromosome Location | chr11:58459236-58460073 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
No data |
No data |
No data |
No data |

No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs484872 | chr11:58459236-58459237 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
2 | rs147410418 | chr11:58459239-58459240 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs549103336 | chr11:58459269-58459270 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs567416464 | chr11:58459286-58459287 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs111438288 | chr11:58459295-58459296 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs117709460 | chr11:58459298-58459299 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs200942627 | chr11:58459302-58459303 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs557309130 | chr11:58459311-58459312 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs371077460 | chr11:58459319-58459320 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
10 | rs368734316 | chr11:58459325-58459326 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs569515083 | chr11:58459370-58459371 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
12 | rs539768761 | chr11:58459371-58459372 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
13 | rs114127617 | chr11:58459412-58459413 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
14 | rs187828376 | chr11:58459457-58459458 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
15 | rs540276052 | chr11:58459478-58459479 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
16 | rs139135363 | chr11:58459528-58459529 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
17 | rs149966257 | chr11:58459542-58459543 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
18 | rs590157 | chr11:58459548-58459549 | Enhancers Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
19 | rs544372288 | chr11:58459551-58459552 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
20 | rs562563416 | chr11:58459570-58459571 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
21 | rs533220088 | chr11:58459658-58459659 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
22 | rs545331692 | chr11:58459711-58459712 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
23 | rs560143411 | chr11:58459719-58459720 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
24 | rs527280947 | chr11:58459807-58459808 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
25 | rs553387227 | chr11:58459849-58459850 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
26 | rs190631139 | chr11:58459859-58459860 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
27 | rs531337685 | chr11:58459860-58459861 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
28 | rs573498019 | chr11:58459870-58459871 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
29 | rs569358216 | chr11:58459903-58459904 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
30 | rs591628 | chr11:58459924-58459925 | Enhancers Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
31 | rs572893874 | chr11:58459945-58459946 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
32 | rs145079490 | chr11:58459974-58459975 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
33 | rs547654 | chr11:58459989-58459990 | Enhancers Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
34 | rs533916251 | chr11:58460006-58460007 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
35 | rs367555987 | chr11:58460018-58460019 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
36 | rs555368485 | chr11:58460034-58460035 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
37 | rs566084 | chr11:58460073-58460074 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
Disease | PMID | Source |
---|---|---|
Medulloblastoma | 21979893 | CNVD |
Gastric cancer | 17908304 | CNVD |
Multiple myeloma | 20724749 | CNVD |
Wilms tumour | 21544195 | CNVD |
Autism | 22495311 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Non-small cell lung cancer | 21385341 | CNVD |
Intellectual disability | 22102821 | CNVD |
Glioblastoma multiforme | 21138945 | CNVD |
Esophageal cancer | 21851588 | CNVD |
Acute myeloid leukemia | 20729466 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Glioblastoma multiforme | 22286061 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Cancer | 21637783 | CNVD |
Acute myeloid leukemia | 16864856 | CNVD |
Chronic lymphocytic leukemia | 21795749 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Neuroblastoma | 21484798 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Oral cancer | 21386901 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 20837533 | CNVD |
Breast cancer | 21264507 | CNVD |
Cervical cancer | 21063398 | CNVD |
Glioblastoma multiforme | 19960244 | CNVD |
Liposarcoma | 21253554 | CNVD |
Neuroblastoma | 18923524 | CNVD |
Neuroblastoma | 18664255 | CNVD |
Monoclonal gammopathy of undetermined significance | 17077331 | CNVD |
Multiple myeloma | 17077331 | CNVD |
Neuroblastoma | 17533364 | CNVD |
Breast cancer | 21364760 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Lung cancer | 18438408 | CNVD |
Colorectal cancer | 16272173 | CNVD |
Esophageal squamous carcinoma | 18350619 | CNVD |
Pituitary adenoma | 18645599 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Prostate cancer | 18632612 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Smith-Lemli-Opitz syndrome | 21572526 | CNVD |
Multiple myeloma | 16461302 | CNVD |
Cancer | 16751803 | CNVD |
Seminomas | 18059402 | CNVD |
Autism | 22495309 | CNVD |
Autism | 20808228 | CNVD |
Non-syndromic sensorineural hearing loss | 21293372 | CNVD |
Breast cancer | 22522925 | CNVD |
Non-syndromic sensorineural hearing loss | 17122850 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr11:58456400-58459400 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
2 | chr11:58457200-58461600 | Enhancers | Primary hematopoietic stem cells | blood |
3 | chr11:58457800-58461200 | Enhancers | Primary hematopoietic stem cells short term culture | blood |
4 | chr11:58458400-58459600 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Female | -- |
5 | chr11:58459200-58459800 | Enhancers | Primary neutrophils fromperipheralblood | blood |
6 | chr11:58459400-58460000 | Flanking Active TSS | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
7 | chr11:58459600-58460000 | Flanking Active TSS | Primary hematopoietic stem cells G-CSF-mobilized Female | -- |
8 | chr11:58460000-58460400 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
9 | chr11:58460000-58462000 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Female | -- |